BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Montejo AL, Montejo L, Navarro-Cremades F. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry 2015;28:418-23. [PMID: 26382168 DOI: 10.1097/YCO.0000000000000198] [Cited by in Crossref: 68] [Cited by in F6Publishing: 18] [Article Influence: 13.6] [Reference Citation Analysis]
2 Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr 2019;24:338-47. [PMID: 29792585 DOI: 10.1017/S1092852918000913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
3 Baldwin DS, Hanumanthaiah VB. Vortioxetine in the treatment of major depressive disorder. Future Neurology 2015;10:79-89. [DOI: 10.2217/fnl.14.69] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
4 Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. J Affect Disord 2016;190:357-61. [PMID: 26546771 DOI: 10.1016/j.jad.2015.10.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Kennedy SH, Grouin JM, Cadour S, Robert V, Picarel-Blanchot F. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Hum Psychopharmacol 2018;33. [PMID: 29327372 DOI: 10.1002/hup.2646] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet 2018;57:673-86. [PMID: 29189941 DOI: 10.1007/s40262-017-0612-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 20.0] [Reference Citation Analysis]
7 Mo X, Li Y, Zhu X, Li X, Zhou H, Bi X, Li J. Vortioxetine Derivatives with Amino Acid as Promoiety: Synthesis, Activity, Stability and Preliminary Pharmacokinetic Study. J Pharm Sci 2021;110:3011-9. [PMID: 33891948 DOI: 10.1016/j.xphs.2021.04.011] [Reference Citation Analysis]
8 Frampton JE. Vortioxetine: A Review in Cognitive Dysfunction in Depression. Drugs 2016;76:1675-82. [DOI: 10.1007/s40265-016-0655-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
9 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
10 Li G, Wang X, Ma D. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat 2016;12:523-31. [PMID: 27013879 DOI: 10.2147/NDT.S103173] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Yang KC, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, Bang-Andersen B, Sanchez C, Halldin C, Farde L, Finnema SJ. Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain. Neuropsychopharmacology 2019;44:1706-13. [PMID: 31216565 DOI: 10.1038/s41386-019-0442-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Salagre E, Grande I, Solé B, Sanchez-moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Revista de Psiquiatría y Salud Mental (English Edition) 2018;11:48-59. [DOI: 10.1016/j.rpsmen.2018.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
13 Zareifopoulos N, Papatheodoropoulos C. Effects of 5-HT-7 receptor ligands on memory and cognition. Neurobiol Learn Mem 2016;136:204-9. [PMID: 27780766 DOI: 10.1016/j.nlm.2016.10.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
14 Turan Yücel N, Kandemir Ü, Demir Özkay Ü, Can ÖD. 5-HT1A Serotonergic, α-Adrenergic and Opioidergic Receptors Mediate the Analgesic Efficacy of Vortioxetine in Mice. Molecules 2021;26:3242. [PMID: 34071269 DOI: 10.3390/molecules26113242] [Reference Citation Analysis]
15 Nissen TD, Laursen B, Viardot G, l'Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM. Effects of Vortioxetine and Escitalopram on Electroencephalographic Recordings – A Randomized, Crossover Trial in Healthy Males. Neuroscience 2020;424:172-81. [DOI: 10.1016/j.neuroscience.2019.09.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
16 Greenblatt DJ, Harmatz JS, Chow CR. Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. J Clin Psychopharmacol 2018;38:172-9. [DOI: 10.1097/jcp.0000000000000861] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
17 Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
18 Villas Boas GR, Boerngen de Lacerda R, Paes MM, Gubert P, Almeida WLDC, Rescia VC, de Carvalho PMG, de Carvalho AAV, Oesterreich SA. Molecular aspects of depression: A review from neurobiology to treatment. Eur J Pharmacol 2019;851:99-121. [PMID: 30776369 DOI: 10.1016/j.ejphar.2019.02.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
19 Staroń J, Bugno R, Hogendorf AS, Bojarski AJ. 5-HT1A receptor ligands and their therapeutic applications: review of new patents. Expert Opinion on Therapeutic Patents 2018;28:679-89. [DOI: 10.1080/13543776.2018.1514011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
20 Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr 2019;24:616-27. [PMID: 30802419 DOI: 10.1017/S1092852919000786] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
21 Dhir A, Sarvaiya J. The efficacy of vortioxetine for the treatment of major depressive disorder. Expert Rev Neurother 2014;14:1349-63. [PMID: 25418918 DOI: 10.1586/14737175.2014.987131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]